Quick Answer
OS Therapies Inc reported Net Income of -$28.75 million for fiscal year 2025.
OS Therapies Inc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$28.75M -223.7% |
-$8.88M -14.0% |
-$7.79M | — |
| Diluted EPS | -$0.98 +23.4% |
-$1.28 +12.3% |
-$1.46 | — |
| Total Assets | $6.84M +23.5% |
$5.54M +594.0% |
$798.1K | — |
| Stockholders Equity | -$6.10M -86.6% |
-$3.27M +86.4% |
-$24.02M -36.8% |
-$17.56M |
| R&D Expense | $16.36M +476.3% |
$2.84M -11.7% |
$3.22M | — |
| Operating Income | -$28.71M -321.3% |
-$6.81M -56.9% |
-$4.34M | — |
| Shares Outstanding | 37.11M +77.8% |
20.87M +290.8% |
5.34M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$6.88M | -139.3% | -51.6% |
| Diluted EPS | September 30, 2025 | -$0.21 | -16.7% | -10.5% |
| Total Assets | September 30, 2025 | $8.95M | +352.8% | -13.2% |
| Stockholders Equity | September 30, 2025 | $3.64M | +614.4% | -26.4% |
| R&D Expense | September 30, 2025 | $3.76M | +210.3% | +50.2% |
| Operating Income | September 30, 2025 | -$6.88M | -182.3% | -42.2% |
| Shares Outstanding | September 30, 2025 | 33.27M | +57.1% | +12.2% |
- OS Therapies Inc reported Net Income of -$28.75 million for fiscal year 2025.
- OS Therapies Inc showed a decrease of -223.7% in Net Income compared to the prior fiscal year.
- OS Therapies Inc reported Diluted EPS of $0.98 per share (loss) for fiscal year 2025.
- OS Therapies Inc showed an increase of +23.4% in Diluted EPS compared to the prior fiscal year.
- OS Therapies Inc reported Total Assets of $6.84 million for fiscal year 2025.
- OS Therapies Inc showed an increase of +23.5% in Total Assets compared to the prior fiscal year.
- OS Therapies Inc reported Stockholders Equity of -$6.10 million for fiscal year 2025.
- OS Therapies Inc showed a decrease of -86.6% in Stockholders Equity compared to the prior fiscal year.
- OS Therapies Inc reported R&D Expense of $16.36 million for fiscal year 2025.
- OS Therapies Inc showed an increase of +476.3% in R&D Expense compared to the prior fiscal year.
- OS Therapies Inc reported Operating Income of -$28.71 million for fiscal year 2025.
- OS Therapies Inc showed a decrease of -321.3% in Operating Income compared to the prior fiscal year.
- OS Therapies Inc reported Shares Outstanding of 37.11 million shares for fiscal year 2025.
- OS Therapies Inc showed an increase of +77.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: